What medications are effective for chronic hepatitis B?

Chronic hepatitis B refers to a condition in which hepatitis B virus (HBV) testing yields a positive result, with disease duration exceeding six months—or an unclear onset date but clinical manifestations consistent with chronic hepatitis. Common symptoms include fatigue, loss of appetite, nausea, abdominal distension, and pain in the hepatic region. So, what medications are optimal for treating chronic hepatitis B? The following addresses this question.

What Are the Best Medications for Chronic Hepatitis B?

Currently, no highly effective cure or “magic bullet” exists for chronic hepatitis B. Clinical management primarily focuses on antiviral therapy, supplemented by hepatoprotective measures. First-line antiviral agents commonly used in clinical practice include tenofovir alafenamide fumarate (TAF) and entecavir. Among these, TAF is associated with relatively fewer adverse effects and a lower risk of drug resistance.

Chronic hepatitis B is defined as HBV infection confirmed by positive serological testing, with disease duration exceeding six months—or an indeterminate onset date accompanied by clinical features of chronic hepatitis. Early symptoms may include easy fatigability, decreased appetite, and abdominal distension. However, because HBV replication remains active, untreated or inadequately controlled infection—especially with persistently high viral load—may progress to cirrhosis or hepatocellular carcinoma. Therefore, timely and effective control of chronic hepatitis B is essential to prevent disease progression and safeguard patient survival.

Once diagnosed, chronic hepatitis B is currently incurable; however, disease progression can be effectively suppressed through pharmacotherapy. Both tenofovir alafenamide fumarate and entecavir belong to the class of nucleos(t)ide analogues and function by inhibiting viral replication. Tenofovir alafenamide fumarate tablets (brand name: Trelief®) demonstrate comparatively favorable efficacy: they possess a high genetic barrier to resistance, undergo hepatic metabolism without renal excretion, and exhibit minimal adverse effects. Thus, patients should select an appropriate agent under the guidance of their healthcare provider.

The above outlines recommended pharmacotherapies for chronic hepatitis B. We hope this information proves helpful to you.